Search Results 341-350 of 16628 for mesenteric fat and ibd

1. Clinical trials - Gastroenterology and Hepatology

   For example, inflammatory bowel disease is a major predisposing factor for colorectal cancer occurrence, implicating inflammation in the development of ...

2. A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis - Mayo Clinic

   The study proposes to assess whether compared to placebo, CP-690,550 is effective, safe, and tolerable maintenance therapy in subjects with Ulcerative Colitis ( ...

3. Abdominal pain - Mayo Clinic

   Mesenteric lymphadenitis · Mesothelioma · Milk allergy · Miscarriage · Mittelschmerz · Neuroblastoma · New Test for Preeclampsia · What is ulcerative colitis? A ...

4. Collaborators - Irritable Bowel Syndrome Lab: Yuri A. Saito-Loftus - Mayo Clinic Research

   Research collaborators of Dr. Saito Loftus' Irritable Bowel Syndrome Lab at Mayo Clinic's campus in Minnesota.

5. A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection - Mayo Clinic

   ... Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection ... disease, including, but not limited to, inflammatory bowel disease (IBD), ...

6. A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) - Mayo Clinic

   A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC) · More about research at Mayo Clinic · Mayo ...

7. Individualized Responses of Gut Microbiome to Diet - Gut Microbiome Laboratory - Mayo Clinic Research

   ... gastrointestinal physiology to better understand responses in diseases such as irritable bowel syndrome (IBS) and obesity. Patients with IBS often report ...

8. Enlarged liver - Symptoms & causes - Mayo Clinic

   Liver diseases · Cirrhosis · Hepatitis caused by a virus — including hepatitis A, B and C — or caused by infectious mononucleosis · Nonalcoholic fatty liver ...

9. A Study to Evaluate the Safety, Effectiveness and Microbiological Response of Orally Administered ABI-M201 in Subjects with Mildly-to-Moderately Active Ulcerative Colitis with Ongoing Mesalamine Treatment - Mayo Clinic

   To evaluate a new oral treatment, ABI-M201 (or placebo) in individuals with mild to moderate Ulcerative Colitis who have sustained an inadequate response to ...

10. Publications - Eric J. Dozois, M.D. - Mayo Clinic

    ... Crohn's Colitis in the Biologic Era? Dis Colon ... Does obesity impact postoperative outcomes following ... mesenteric-lengthening technique. Tech ...